Sickle Cell Disease Treatment

Sickle Cell Disease Treatment

Global Sickle Cell Disease Treatment Market to Reach US$8.6 Billion by 2030

The global market for Sickle Cell Disease Treatment estimated at US$2.6 Billion in the year 2023, is expected to reach US$8.6 Billion by 2030, growing at a CAGR of 18.7% over the analysis period 2023-2030. Blood Transfusion, one of the segments analyzed in the report, is expected to record a 19.3% CAGR and reach US$6.5 Billion by the end of the analysis period. Growth in the Bone Marrow Transplant segment is estimated at 17.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$701.6 Million While China is Forecast to Grow at 17.3% CAGR

The Sickle Cell Disease Treatment market in the U.S. is estimated at US$701.6 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 17.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.0% and 16.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.4% CAGR.

Global Sickle Cell Disease Treatment Market - Key Trends and Drivers Summarized

Why Is Sickle Cell Disease Treatment Gaining Global Attention?
Sickle cell disease (SCD) treatment is gaining significant global attention due to its rising prevalence and the severe impact it has on the quality of life of patients. Sickle cell disease is a hereditary blood disorder characterized by abnormally shaped red blood cells, which can cause severe pain, frequent infections, and other life-threatening complications. Predominantly affecting people of African, Mediterranean, South Asian, and Middle Eastern descent, SCD is becoming a major public health concern, especially in regions like Sub-Saharan Africa, where the disease burden is particularly high. Efforts to improve early diagnosis, increase awareness, and develop comprehensive care frameworks are driving the demand for effective treatment solutions, including pain management, hydroxyurea therapy, blood transfusions, and bone marrow transplants.

How Are Technological Advancements Revolutionizing Sickle Cell Disease Treatment?
Technological advancements are revolutionizing sickle cell disease treatment by introducing innovative therapies such as gene therapy and CRISPR-based genome editing. These advanced treatments aim to provide a one-time cure by correcting the defective gene responsible for the disease, unlike conventional therapies that primarily focus on symptom management. Several gene therapies, including Lentiglobin, are currently under clinical trials, showing promise in reversing the effects of SCD and reducing the need for regular blood transfusions and pain management. The advent of personalized medicine, which involves tailoring treatment plans based on the genetic makeup of the individual, is further enhancing the effectiveness of these therapies. In addition to gene therapy, other novel approaches such as voxelotor and L-glutamine therapies are expanding the range of available treatment options, providing relief from symptoms and improving patient outcomes.

Which Market Segments Are Leading the Adoption of Sickle Cell Disease Treatment?
Treatment types include pharmacotherapy, blood transfusion, bone marrow transplant, and gene therapy, with pharmacotherapy being the most widely adopted due to its accessibility and affordability. However, gene therapy is expected to grow at the fastest rate due to its potential as a curative treatment. End-users of SCD treatments include hospitals, specialty clinics, and research organizations, with hospitals being the primary adopters due to their role in providing comprehensive care and managing complications associated with the disease. Geographically, North America and Europe are the leading markets for SCD treatment due to advanced healthcare infrastructures, ongoing clinical trials, and regulatory support for orphan drug development. Meanwhile, Africa and the Middle East are emerging as key markets due to the high prevalence of SCD and increasing government initiatives for improved healthcare access.

What Are the Key Drivers of Growth in the Sickle Cell Disease Treatment Market?
The growth in the sickle cell disease treatment market is driven by several factors, including the rising prevalence of sickle cell disease globally, advancements in gene therapy and CRISPR technology, and increasing investment in R&D for targeted therapies and biological drugs. The development of curative therapies, novel drug combinations, and cell-based therapies is driving market adoption among hospitals, specialty clinics, and research organizations. The focus on enhancing early diagnosis, personalized medicine, and patient-centric care models is expanding the market reach among pediatric and adult patients. The growing use of telemedicine and digital health platforms for SCD management, coupled with the demand for affordable and accessible treatment solutions, is creating new opportunities for market growth. Additionally, the increasing collaboration between research institutions, pharmaceutical companies, and non-profit organizations for developing innovative treatments is further supporting market expansion.

Select Competitors (Total 13 Featured) -

• Acceleron Pharma, Inc.
• Alnylam Pharmaceuticals, Inc.
• Arena Pharmaceuticals, Inc.
• AstraZeneca PLC
• Baxter International, Inc.
• bluebird bio, Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Emmaus Life Sciences, Inc.
• Global Blood Therapeutics, Inc.
• Novartis AG
• Pfizer, Inc.
• Sangamo Therapeutics, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.